OCUGEN, INC. Research and Development Expense
OCUGEN, INC. (OCGN) reported Research and Development Expense of $10.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- OCUGEN, INC. research and development expense for the quarter ending 2026-06-30 was $10.69M, a 27.23% increase year-over-year.
- OCUGEN, INC. research and development expense for the quarter ending 2026-03-31 was $11.26M, a 18.11% increase year-over-year.
- OCUGEN, INC. research and development expense for the quarter ending 2025-12-31 was $10.67M, a 28.70% increase year-over-year.
- OCUGEN, INC. research and development expense for the quarter ending 2025-09-30 was $11.15M, a 37.51% increase year-over-year.
- OCUGEN, INC. research and development expense for fiscal 2025 was $39.75M, a 23.73% increase from fiscal 2024.
- OCUGEN, INC. research and development expense for fiscal 2024 was $32.13M, a 18.82% decline from fiscal 2023.
- OCUGEN, INC. research and development expense for fiscal 2023 was $39.57M.
- OCUGEN, INC. research and development expense for fiscal 2019 was $8.09M, a 21.66% decline from fiscal 2018.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $10.69M 10-Q · filed 2026-08-06 | $21.95M 10-Q · filed 2026-08-06 | $32.61M derived: sum of 3 quarters · filed 2026-08-06 | $43.76M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $11.26M 10-Q · filed 2026-05-08 | $21.92M derived: sum of 2 quarters · filed 2026-05-08 | $33.07M derived: sum of 3 quarters · filed 2026-05-08 | $41.48M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $10.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $21.82M derived: sum of 2 quarters · filed 2026-03-04 | $30.22M derived: sum of 3 quarters · filed 2026-08-06 | $39.75M 10-K · filed 2026-03-04 | ||||
| 2025-09-30 | $11.15M 10-Q · filed 2025-11-05 | $19.55M derived: sum of 2 quarters · filed 2026-08-06 | $29.08M 10-Q · filed 2025-11-05 | $37.37M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $8.40M 10-Q · filed 2026-08-06 | $17.93M 10-Q · filed 2026-08-06 | $26.22M derived: sum of 3 quarters · filed 2026-08-06 | $34.33M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $9.53M 10-Q · filed 2026-05-08 | $17.82M derived: sum of 2 quarters · filed 2026-05-08 | $25.93M derived: sum of 3 quarters · filed 2026-05-08 | $34.83M derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $8.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $16.40M derived: sum of 2 quarters · filed 2026-03-04 | $25.30M derived: sum of 3 quarters · filed 2026-03-04 | $32.13M 10-K · filed 2026-03-04 | ||||
| 2024-09-30 | $8.11M 10-Q · filed 2025-11-05 | $17.01M derived: sum of 2 quarters · filed 2025-11-05 | $23.84M 10-Q · filed 2025-11-05 | |||||
| 2024-06-30 | $8.90M 10-Q · filed 2025-08-04 | $15.73M 10-Q · filed 2025-08-04 | ||||||
| 2024-03-31 | $6.83M 10-Q · filed 2025-05-09 | |||||||
| 2023-12-31 | $39.57M 10-K · filed 2025-03-05 | |||||||
| 2020-03-31 | $1.65M 10-Q · filed 2020-05-08 | $3.40M derived: sum of 2 quarters · filed 2020-05-08 | $4.70M derived: sum of 3 quarters · filed 2020-05-08 | $5.94M derived: sum of 4 quarters · filed 2020-05-08 | ||||
| 2019-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $3.05M derived: sum of 2 quarters · filed 2020-03-27 | $4.29M derived: sum of 3 quarters · filed 2020-03-27 | $8.09M 10-K · filed 2020-03-27 | ||||
| 2019-09-30 | $1.31M 10-Q · filed 2019-11-12 | $2.55M derived: sum of 2 quarters · filed 2019-11-12 | $6.34M 10-Q · filed 2019-11-12 | $9.25M derived: sum of 4 quarters · filed 2020-05-08 | ||||
| 2019-06-30 | $1.24M 8-K/A · filed 2019-10-07 | $446.00K 10-Q · filed 2019-08-09 | $5.03M 8-K/A · filed 2019-10-07 | $2.03M 10-Q · filed 2019-08-09 | $7.95M derived: sum of 3 quarters · filed 2020-05-08 | $9.51M derived: sum of 4 quarters · filed 2020-05-08 | ||
| 2019-03-31 | $3.79M 10-Q · filed 2020-05-08 | $1.58M 10-Q · filed 2019-05-15 | $6.71M derived: sum of 2 quarters · filed 2020-05-08 | $8.27M derived: sum of 3 quarters · filed 2020-05-08 | $11.10M derived: sum of 4 quarters · filed 2020-05-08 | |||
| 2018-12-31 | $2.92M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $4.48M derived: sum of 2 quarters · filed 2020-03-27 | $7.31M derived: sum of 3 quarters · filed 2020-03-27 | $10.32M 10-K · filed 2020-03-27 | $15.63M 10-K · filed 2019-03-22 | |||
| 2018-09-30 | $1.56M 10-Q · filed 2019-11-12 | $4.56M 10-Q · filed 2018-11-08 | $4.39M derived: sum of 2 quarters · filed 2019-11-12 | $7.41M 10-Q · filed 2019-11-12 | $12.31M 10-Q · filed 2018-11-08 | $11.05M derived: sum of 4 quarters · filed 2019-11-12 | ||
| 2018-06-30 | $2.83M 8-K/A · filed 2019-10-07 | $4.46M 10-Q · filed 2018-08-09 | $5.84M 8-K/A · filed 2019-10-07 | $7.74M 10-Q · filed 2018-08-09 | $9.48M derived: sum of 3 quarters · filed 2019-10-07 | $12.97M derived: sum of 4 quarters · filed 2019-10-07 | ||
| 2018-03-31 | $3.29M 10-Q · filed 2019-05-15 | $6.65M derived: sum of 2 quarters · filed 2019-05-15 | $10.14M derived: sum of 3 quarters · filed 2019-05-15 | $14.35M derived: sum of 4 quarters · filed 2019-05-15 | ||||
| 2017-12-31 | $3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $6.85M derived: sum of 2 quarters · filed 2019-03-22 | $11.06M derived: sum of 3 quarters · filed 2019-03-22 | $15.57M 10-K · filed 2019-03-22 | ||||
| 2017-09-30 | $3.49M 10-Q · filed 2018-11-08 | $7.70M derived: sum of 2 quarters · filed 2018-11-08 | $12.20M 10-Q · filed 2018-11-08 | $17.52M derived: sum of 4 quarters · filed 2018-11-08 | ||||
| 2017-06-30 | $4.21M 10-Q · filed 2018-08-09 | $8.71M 10-Q · filed 2018-08-09 | $14.03M derived: sum of 3 quarters · filed 2018-08-09 | $18.91M derived: sum of 4 quarters · filed 2018-08-09 | ||||
| 2017-03-31 | $4.50M 10-Q · filed 2018-05-10 | $9.82M derived: sum of 2 quarters · filed 2018-05-10 | $14.70M derived: sum of 3 quarters · filed 2018-05-10 | $20.50M derived: sum of 4 quarters · filed 2018-05-10 | ||||
| 2016-12-31 | $5.32M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $10.20M derived: sum of 2 quarters · filed 2018-03-15 | $15.99M derived: sum of 3 quarters · filed 2018-03-15 | $21.58M 10-K · filed 2018-03-15 | ||||
| 2016-09-30 | $4.88M 10-Q · filed 2017-11-09 | $10.67M derived: sum of 2 quarters · filed 2017-11-09 | $16.26M 10-Q · filed 2017-11-09 | $22.03M derived: sum of 4 quarters · filed 2017-11-09 | ||||
| 2016-06-30 | $5.79M 10-Q · filed 2017-08-10 | $11.38M 10-Q · filed 2017-08-10 | $17.15M derived: sum of 3 quarters · filed 2017-08-10 | $23.00M derived: sum of 4 quarters · filed 2017-08-10 | ||||
| 2016-03-31 | $5.59M 10-Q · filed 2017-05-11 | $11.36M derived: sum of 2 quarters · filed 2017-05-11 | $17.21M derived: sum of 3 quarters · filed 2017-05-11 | $23.07M derived: sum of 4 quarters · filed 2017-05-11 | ||||
| 2015-12-31 | $5.77M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $11.62M derived: sum of 2 quarters · filed 2017-03-16 | $17.48M derived: sum of 3 quarters · filed 2017-03-16 | $23.24M 10-K · filed 2017-03-16 | ||||
| 2015-09-30 | $5.85M 10-Q · filed 2016-11-10 | $11.71M derived: sum of 2 quarters · filed 2016-11-10 | $17.47M 10-Q · filed 2016-11-10 | $22.23M derived: sum of 4 quarters · filed 2016-11-10 | ||||
| 2015-06-30 | $5.86M 10-Q · filed 2016-08-11 | $11.62M 10-Q · filed 2016-08-11 | $16.38M derived: sum of 3 quarters · filed 2016-08-11 | $29.62M derived: sum of 4 quarters · filed 2016-08-11 | ||||
| 2015-03-31 | $5.76M 10-Q · filed 2016-05-12 | -$5.76M 10-Q · filed 2015-05-14 | $10.52M derived: sum of 2 quarters · filed 2016-05-12 | $23.76M derived: sum of 3 quarters · filed 2016-05-12 | $28.43M derived: sum of 4 quarters · filed 2016-05-12 | |||
| 2014-12-31 | $4.76M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $17.99M derived: sum of 2 quarters · filed 2016-03-10 | $22.66M derived: sum of 3 quarters · filed 2016-03-10 | $26.04M 10-K · filed 2016-03-10 | ||||
| 2014-09-30 | $13.24M 10-Q · filed 2015-11-12 | $17.91M derived: sum of 2 quarters · filed 2015-11-12 | $21.28M 10-Q · filed 2015-11-12 | |||||
| 2014-06-30 | $4.67M 10-Q · filed 2015-08-12 | $8.04M 10-Q · filed 2015-08-12 | ||||||
| 2014-03-31 | -$3.37M 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |